Watch ENVB. Know when insiders buy.
One email the day a filing lands. Free.
ENVB
Enveric Biosciences, Inc.
1.42
−0.04 −2.74%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
77
PASS · shorts 77
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $6.4MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$8.7MNET CASH $2.1M52W 1.27 – 11.64SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$3M | −$3M | — | -0.76 | −$2.4M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$1.6M | −$1.6M | — | -1.08 | −$2.3M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.2M | −$2.2M | — | -0.50 | −$1.8M | — | — | Mar 27 |
| Q3 2025 · Sep 30 | — | — | — | −$1.9M | −$1.9M | — | -10.81 | −$2.1M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$2.5M | −$2.5M | — | -11.65 | −$1.9M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$2.2M | −$2.2M | — | -14.58 | −$2.4M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$3.2M | −$3.2M | — | -57.81 | −$1.3M | — | — | Mar 27 |
| Q3 2024 · Sep 30 | — | — | — | −$2.1M | −$2.1M | — | -43.10 | −$927K | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$1.9M | −$1.9M | — | -3.72 | −$2.9M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$2.5M | −$2.5M | — | -9.21 | −$2.6M | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$2.4M | −$3.4M | — | -114.67 | −$1.8M | −$15 | −$1.8M | Mar 28 |
| Q3 2023 · Sep 30 | — | — | — | −$3.4M | −$2.8M | — | -1.30 | −$2.7M | $8 | −$2.7M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$8.8M | −$8.8M | — | -36.24 | −$8.1M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$9.6M | −$9.6M | — | -228.48 | −$7.7M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$16.4M | −$17.3M | — | -121.29 | −$14.1M | $5K | −$14.1M | — | — |
| FY2022 · to Dec 31 | — | — | −$27.4M | −$18.5M | — | -13.00 | −$17.1M | $584K | −$17.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$64.6M | −$49M | — | -2.07 | −$11.5M | $190K | −$11.6M | — | — |
| FY2020 · to Dec 31 | — | — | −$5.6M | −$6.9M | — | -1.19 | −$3.9M | — | — | — | — |
Every number comes from Enveric Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.